Cassava Sciences (SAVA) 10-Q 23 Jul 15 2015 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Jul. 10, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Trading Symbol	PTIE
Entity Registrant Name	PAIN THERAPEUTICS INC
Entity Central Index Key	1,069,530
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		45,756,117

Condensed Balance Sheets

Condensed Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014	[1]
Current assets:
Cash and cash equivalents	$ 36,352	$ 40,590
Marketable securities	950
Other current assets	200	239
Total current assets	37,502	40,829
Property and equipment, net	242	65
Other assets	12	12
Total assets	37,756	40,906
Current liabilities:
Accounts payable	465	173
Accrued development expense	448	25
Accrued compensation and benefits	900	652
Total current liabilities	$ 1,813	$ 850
Noncurrent liabilities
Total liabilities	$ 1,813	$ 850
Commitments and contingencies
Stockholders' equity:
Preferred stock
Common stock	$ 46	$ 46
Additional paid-in capital	158,346	156,502
Accumulated other comprehensive income	1	1
Accumulated deficit	(122,450)	(116,493)
Total stockholders' equity	35,943	40,056
Total liabilities and stockholders' equity	$ 37,756	$ 40,906
[1]	Derived from the Company's audited financial statements as of December 31, 2014, included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission.

Condensed Statements Of Operati

Condensed Statements Of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Operating expenses:
Research and development	$ 1,986	$ 1,935	$ 3,124	$ 4,081
General and administrative	1,401	1,322	2,858	2,639
Total operating expenses	3,387	3,257	5,982	6,720
Operating loss	(3,387)	(3,257)	(5,982)	(6,720)
Interest income	13	11	25	25
Net loss	$ (3,374)	$ (3,246)	$ (5,957)	$ (6,695)
Net loss per share, basic and diluted	$ (0.07)	$ (0.07)	$ (0.13)	$ (0.15)
Weighted-average shares used in computing net loss per share, basic and diluted	45,356	45,247	45,356	45,187

Condensed Statements Of Compreh

Condensed Statements Of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Condensed Statements Of Comprehensive Loss [Abstract]
Net loss	$ (3,374)	$ (3,246)	$ (5,957)	$ (6,695)
Other comprehensive income (losses):
Net unrealized losses on marketable securities		(1)		(1)
Comprehensive loss	$ (3,374)	$ (3,247)	$ (5,957)	$ (6,696)

Condensed Statements Of Cash Fl

Condensed Statements Of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015		Jun. 30, 2014
Cash flows used in operating activities:
Net loss	$ (5,957)		$ (6,695)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash stock based compensation	1,844		1,667
Depreciation and amortization	18		7
Non-cash net interest income	(2)		(2)
Changes in operating assets and liabilities:
Other current assets	39		(217)
Other assets			(12)
Accounts payable	292		(85)
Accrued development expense	423		(309)
Accrued compensation and benefits	248		335
Other current liabilities			(3)
Net cash used in operating activities	(3,095)		(5,314)
Cash flows used in investing activities:
Purchases of property and equipment	(195)		(79)
Purchases of marketable securities	(2,948)		(1,499)
Maturities of marketable securities	2,000		2,500
Net cash provided by (used in) investing activities	(1,143)		922
Cash flows provided by financing activities:
Proceeds from issuance of common stock, net			379
Net cash provided by financing activities			379
Net decrease in cash and cash equivalents	(4,238)		(4,013)
Cash and cash equivalents at beginning of the period	40,590	[1]	48,588
Cash and cash equivalents at end of the period	$ 36,352		$ 44,575
[1]	Derived from the Company's audited financial statements as of December 31, 2014, included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission.

General

General	6 Months Ended
	Jun. 30, 2015
General [Abstract]
General	Note 1. General We are a biopharmaceutical company that develops novel drugs. We own world-wide commercial rights to our lead drug candidate, REMOXY Extended-Release Capsules CII, a unique, twice-a-day formulation of oral oxycodone. REMOXY’s intended indication is for the management of moderate-to-severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time and for which alternative treatments are inadequate. We specifically developed REMOXY to discourage certain common methods of drug tampering and misuse. The REMOXY NDA is supported by multiple clinical trials, including a successful Phase III efficacy program that was conducted under a Special Protocol Assessment. In the course of our development activities, we have sustained cumulative operating losses. There are no assurances that additional financing will be available on favorable terms, or at all. We have prepared the accompanying unaudited condensed financial statements of Pain Therapeutics, Inc. in accordance with generally accepted accounting principles for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In our opinion, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2015 are not necessarily indicative of the results that may be expected for any other interim period or for the year 2015 . For further information, refer to the consolidated financial statements and footnotes thereto included in our annual report on Form 10-K for the year ended December 31, 2014. We have evaluated subsequent events through the date of filing this Form 10-Q.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2015
Significant Accounting Policies [Abstract]
Significant Accounting Policies	Note 2. Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. Actual results could differ from those estimates . Cash, Cash Equivalents and Concentration of Credit Risk We consider all highly liquid financial instruments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents consist of cash maintained at one financial institution and in money market funds. We believe the financial risks associated with these instruments are minimal. We have not experienced material losses from our investments in these securities. Marketable Securities and Fair Value Measurements We invest in interest bearing marketable securities, generally consisting of corporate and government securities. We may elect to sell these investments before they mature. Therefore, we hold these investments as “available for sale” and include these investments in our balance sheets as current assets, even though the contractual maturity of a particular investment may be beyond one year. We report our marketable securities at fair value, which may include unrealized gains and losses. Our unrealized gains and losses on investments are recorded as a separate component of stockholders’ equity as accumulated other comprehensive income or loss. We recognize all realized gains and losses on our marketable securities on a specific identification basis in interest income in our Statements of Operations. We report changes in net unrealized gains or losses on marketable securities in our Statements of Comprehensive Income. Our marketable securities are maintained at one financial institution and are governed by our investment policy as approved by our Board of Directors. To date we have no t recorded any impairment charges on marketable securities related to other - than - temporary declines in market value. We would recognize an impairment charge when the decline in the estimated fair value of a marketable security below the amortized cost is determined to be other-than-temporary. We consider various factors in determining whether to recognize an impairment charge, including any adverse changes in the investees’ financial condition, how long the fair value has been below the amortized cost and whether it is more likely than not that we would elect to or be required to sell the marketable security before its anticipated recovery. We measure our cash equivalents and marketable securities at fair value on a recurring basis. We use significant observable inputs where there are identical or comparable assets in the market to use in establishing our fair value measurements, including but not limited to benchmark yields, reported trades, broker/dealer quotes and issuer spreads. We consider these inputs to be Level 2 inputs. Generally, the types of instruments we invest in are not traded on a market such as the NASDAQ Global Market, which we would consider to be Level 1 inputs. We do not have any investments that would require inputs considered to be Level 3. We use the bid price to establish fair value where a bid price is available. Stock-based Compensation We recognize expense for the fair value of all share-based payments, including grants of employee stock options and other share based awards, in our Statements of Operations. For stock options, we use the Black-Scholes option valuation model and the single-option award approach and straight-line attribution method. Using this approach, the compensation cost is amortized on a straight-line basis over the vesting period of each respective stock option, generally four years. We estimate forfeitures and adjust this estimate periodically based on the extent to which future actual forfeitures differ, or are expected to differ, from such estimates. We have granted share-based awards that vest upon achievement of certain performance criteria, or Performance Awards. The value of these awards is the product of the number of shares of our common stock to be issued under the award multiplied by the fair market value of a share of our common stock on the date of grant. These awards include future performance criteria. We estimate an implicit service period for achieving these performance criteria. Performance Awards vest and common stock is issued on achieving performance criteria. We recognize stock-based compensation expense for Performance Awards when we conclude that achieving performance criteria is probable. We periodically review and update as appropriate our estimates of the implicit service periods and the likelihood of achieving the performance criteria. Net Loss per Share We compute basic net loss per share on the basis of the weighted-average number of common shares outstanding for the reporting period. We compute diluted net loss per share on the basis of the weighted-average number of common shares outstanding plus dilutive potential common shares outstanding using the treasury-stock method. Potential dilutive common shares consist of outstanding stock options and Performance Awards. The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands except per share data): Three months ended Six months ended June 30, June 30, 2015 2014 2015 2014 Numerator: Net loss $ $ $ $ Denominator: Weighted-average shares used in computing net loss per share, basic and diluted Net loss per share, basic and diluted $ $ $ $ We excluded weighted options outstanding to purchase common stock of 17.7 million for the second quarter of 2015, 17.7 million for the first six months of 2015, 5.5 million for the second quarter of 2014 and 5.0 million for the first six months of 2014 from the calculation of diluted net loss per share because the effect of including these shares in this calculation would be anti - dilutive. Income Taxes We make estimates and judgments in determining the need for a provision for income taxes, including the estimation of our taxable income or loss for each full fiscal year. We have accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. We are uncertain about the timing and amount of any future earnings. Accordingly, we offset these deferred tax assets with a valuation allowance. We may in the future determine that certain deferred tax assets will likely be realized, in which case we will reduce our valuation allowance in the period in which such determination is made. If the valuation allowance is reduced, we may recognize a benefit from income taxes in our statement of operations in that period. We classify interest recognized pursuant to our deferred tax assets as interest expense, when appropriate.

Cash, Cash Equivalents And Mark

Cash, Cash Equivalents And Marketable Securities And Assets Measured At Fair Value	6 Months Ended
	Jun. 30, 2015
Cash, Cash Equivalents And Marketable Securities And Assets Measured At Fair Value [Abstract]
Cash, Cash Equivalents And Marketable Securities And Assets Measured At Fair Value	Note 3. Cash, Cash Equivalents and Marketable Securities and Assets Measured at Fair Value Our cash, cash equivalents and marketable securities are as follows (in thousands): Cash, Cash Equivalents and Marketable Securities Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Accrued Interest Total Value June 30, 2015 Cash $ $ — $ — $ $ — $ Cash equivalents — — — Commercial paper — — $ $ $ — $ $ — $ Reported as: Cash and cash equivalents $ $ — $ — $ $ — $ Marketable securities — — $ $ $ — $ $ — $ Maturities: Matures in one year or less $ $ $ — $ $ — $ Matures one to three years — — — — — — $ $ $ — $ $ — $ December 31, 2014 Cash $ $ — $ — $ $ — $ Cash equivalents — — — Commercial paper — — Corporate securities — — $ $ $ — $ $ $ Reported as: Cash and cash equivalents $ $ $ — $ $ $ $ $ $ — $ $ $ Maturities: Matures in one year or less $ $ $ — $ $ $ Matures one to three years — — — — — — $ $ $ — $ $ $ We did not realize any gains or losses on our investments in marketable securities during the first three and six months of 2015 or 2014. To date we have not recorded any impairment charges on marketable securities related to other-than-temporary declines in market value. Our assets measured at fair value on a recurring basis are as follows (in thousands): Level 1 Level 2 Level 3 Total June 30, 2015 Cash and cash equivalents $ $ — $ — $ Commercial paper — — $ $ $ — $ December 31, 2014 Cash and cash equivalents $ $ — $ — $ Commercial paper — — Corporate securities — — $ $ $ — $

Equity And Stock-Based Compensa

Equity And Stock-Based Compensation Expense	6 Months Ended
	Jun. 30, 2015
Equity And Stock-Based Compensation Expense [Abstract]
Equity And Stock-Based Compensation Expense	Note 4. Equity and Stock-Based Compensation Expense Our stock option and Performance Award activity during 2015 was as follows: Number of Options Number of Performance Awards Outstanding as of December 31, 2014 Granted Exercised — — Cancelled Outstanding as of June 30, 2015 Our non-cash stock-based compensation expenses were as follows (in thousands): Three months ended Six months ended June 30, June 30, 2015 2014 2015 2014 Research and development $ $ $ $ General and administrative $ $ $ $

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2015
Income Taxes [Abstract]
Income Taxes	Note 5. Income Taxes We did not provide for income taxes in 2015 because we have projected a net loss for the full year 2015.

Commitments

Commitments	6 Months Ended
	Jun. 30, 2015
Commitments [Abstract]
Commitments	Note 6. Commitments We conduct our product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. We have contractual arrangements with these organizations that are cancelable. Our obligations under these contracts are largely based on services performed. We have a non-cancelable operating lease for approximately 6,000 square feet of office space in Austin, Texas that expires in December 2017 . Minimum lease payments are as follows (in thousands): 2015 2016 2017 Total Minimum lease payments $ $ $ $

Legal Proceedings

Legal Proceedings	6 Months Ended
	Jun. 30, 2015
Legal Proceedings [Abstract]
Legal Proceedings	Note 7. Legal Proceedings KB Partners I, L.P., Individually and On Behalf of All Others Similarly Situated v. Pain Therapeutics, Inc., Remi Barbier, Nadav Friedmann and Peter S. Roddy. On December 2, 2011, a purported class action was filed against us and our executive officers in the U.S. District Court for the Western District of Texas. This complaint alleges, among other things, violations of S ection 10(b), Rule 10b-5, and Section 20(a) of the Securities and Exchange Act of 1934, as amended, arising out of allegedly untrue or misleading statements of material facts made by us regarding REMOXY’s development and regulatory status during the purported class period, February 3, 2011 through June 23, 2011. The complaint states that monetary damages are being sought, but no amounts are specified. On June 3, 2013, the Court certified a class consisting of all purchasers of our common stock and a class period of December 27, 2010 through June 26, 2011. On July 7, 2015, the Court set a new trial date of March 2017.

Recently Issued Accounting Pron

Recently Issued Accounting Pronouncements	6 Months Ended
	Jun. 30, 2015
Recently Issued Accounting Pronouncements [Abstract]
Recently Issued Accounting Pronouncements	Note 8. Recently Issued Accounting Pronouncements We reviewed recently issued accounting pronouncements and have adopted or plan to adopt those that are applicable to us. We do not expect the adoption of these pronouncements to have a material impact on our financial position, results of operations or cash flows.

Significant Accounting Polici14

Significant Accounting Policies (Policy)	6 Months Ended
	Jun. 30, 2015
Significant Accounting Policies [Abstract]
Use Of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. Actual results could differ from those estimates .
Cash, Cash Equivalents And Concentration Of Credit Risk	Cash, Cash Equivalents and Concentration of Credit Risk We consider all highly liquid financial instruments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents consist of cash maintained at one financial institution and in money market funds. We believe the financial risks associated with these instruments are minimal. We have not experienced material losses from our investments in these securities.
Marketable Securities And Fair Value Measurements	Marketable Securities and Fair Value Measurements We invest in interest bearing marketable securities, generally consisting of corporate and government securities. We may elect to sell these investments before they mature. Therefore, we hold these investments as “available for sale” and include these investments in our balance sheets as current assets, even though the contractual maturity of a particular investment may be beyond one year. We report our marketable securities at fair value, which may include unrealized gains and losses. Our unrealized gains and losses on investments are recorded as a separate component of stockholders’ equity as accumulated other comprehensive income or loss. We recognize all realized gains and losses on our marketable securities on a specific identification basis in interest income in our Statements of Operations. We report changes in net unrealized gains or losses on marketable securities in our Statements of Comprehensive Income. Our marketable securities are maintained at one financial institution and are governed by our investment policy as approved by our Board of Directors. To date we have no t recorded any impairment charges on marketable securities related to other - than - temporary declines in market value. We would recognize an impairment charge when the decline in the estimated fair value of a marketable security below the amortized cost is determined to be other-than-temporary. We consider various factors in determining whether to recognize an impairment charge, including any adverse changes in the investees’ financial condition, how long the fair value has been below the amortized cost and whether it is more likely than not that we would elect to or be required to sell the marketable security before its anticipated recovery. We measure our cash equivalents and marketable securities at fair value on a recurring basis. We use significant observable inputs where there are identical or comparable assets in the market to use in establishing our fair value measurements, including but not limited to benchmark yields, reported trades, broker/dealer quotes and issuer spreads. We consider these inputs to be Level 2 inputs. Generally, the types of instruments we invest in are not traded on a market such as the NASDAQ Global Market, which we would consider to be Level 1 inputs. We do not have any investments that would require inputs considered to be Level 3. We use the bid price to establish fair value where a bid price is available.
Stock-Based Compensation	Stock-based Compensation We recognize expense for the fair value of all share-based payments, including grants of employee stock options and other share based awards, in our Statements of Operations. For stock options, we use the Black-Scholes option valuation model and the single-option award approach and straight-line attribution method. Using this approach, the compensation cost is amortized on a straight-line basis over the vesting period of each respective stock option, generally four years. We estimate forfeitures and adjust this estimate periodically based on the extent to which future actual forfeitures differ, or are expected to differ, from such estimates. We have granted share-based awards that vest upon achievement of certain performance criteria, or Performance Awards. The value of these awards is the product of the number of shares of our common stock to be issued under the award multiplied by the fair market value of a share of our common stock on the date of grant. These awards include future performance criteria. We estimate an implicit service period for achieving these performance criteria. Performance Awards vest and common stock is issued on achieving performance criteria. We recognize stock-based compensation expense for Performance Awards when we conclude that achieving performance criteria is probable. We periodically review and update as appropriate our estimates of the implicit service periods and the likelihood of achieving the performance criteria.
Net Loss Per Share	Net Loss per Share We compute basic net loss per share on the basis of the weighted-average number of common shares outstanding for the reporting period. We compute diluted net loss per share on the basis of the weighted-average number of common shares outstanding plus dilutive potential common shares outstanding using the treasury-stock method. Potential dilutive common shares consist of outstanding stock options and Performance Awards. The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands except per share data): Three months ended Six months ended June 30, June 30, 2015 2014 2015 2014 Numerator: Net loss $ $ $ $ Denominator: Weighted-average shares used in computing net loss per share, basic and diluted Net loss per share, basic and diluted $ $ $ $ We excluded weighted options outstanding to purchase common stock of 17.7 million for the second quarter of 2015, 17.7 million for the first six months of 2015, 5.5 million for the second quarter of 2014 and 5.0 million for the first six months of 2014 from the calculation of diluted net loss per share because the effect of including these shares in this calculation would be anti - dilutive.
Income Taxes	Income Taxes We make estimates and judgments in determining the need for a provision for income taxes, including the estimation of our taxable income or loss for each full fiscal year. We have accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. We are uncertain about the timing and amount of any future earnings. Accordingly, we offset these deferred tax assets with a valuation allowance. We may in the future determine that certain deferred tax assets will likely be realized, in which case we will reduce our valuation allowance in the period in which such determination is made. If the valuation allowance is reduced, we may recognize a benefit from income taxes in our statement of operations in that period. We classify interest recognized pursuant to our deferred tax assets as interest expense, when appropriate.

Significant Accounting Polici15

Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2015
Significant Accounting Policies [Abstract]
Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share	Three months ended Six months ended June 30, June 30, 2015 2014 2015 2014 Numerator: Net loss $ $ $ $ Denominator: Weighted-average shares used in computing net loss per share, basic and diluted Net loss per share, basic and diluted $ $ $ $

Cash, Cash Equivalents And Ma16

Cash, Cash Equivalents And Marketable Securities And Assets Measured At Fair Value (Tables)	6 Months Ended
	Jun. 30, 2015
Cash, Cash Equivalents And Marketable Securities And Assets Measured At Fair Value [Abstract]
Cash, Cash Equivalents And Marketable Securities	Cash, Cash Equivalents and Marketable Securities Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Accrued Interest Total Value June 30, 2015 Cash $ $ — $ — $ $ — $ Cash equivalents — — — Commercial paper — — $ $ $ — $ $ — $ Reported as: Cash and cash equivalents $ $ — $ — $ $ — $ Marketable securities — — $ $ $ — $ $ — $ Maturities: Matures in one year or less $ $ $ — $ $ — $ Matures one to three years — — — — — — $ $ $ — $ $ — $ December 31, 2014 Cash $ $ — $ — $ $ — $ Cash equivalents — — — Commercial paper — — Corporate securities — — $ $ $ — $ $ $ Reported as: Cash and cash equivalents $ $ $ — $ $ $ $ $ $ — $ $ $ Maturities: Matures in one year or less $ $ $ — $ $ $ Matures one to three years — — — — — — $ $ $ — $ $ $
Assets Measured At Fair Value On Recurring Basis	Level 1 Level 2 Level 3 Total June 30, 2015 Cash and cash equivalents $ $ — $ — $ Commercial paper — — $ $ $ — $ December 31, 2014 Cash and cash equivalents $ $ — $ — $ Commercial paper — — Corporate securities — — $ $ $ — $

Equity And Stock-Based Compen17

Equity And Stock-Based Compensation Expense (Tables)	6 Months Ended
	Jun. 30, 2015
Equity And Stock-Based Compensation Expense [Abstract]
Stock Option And Performance Award Activity	Number of Options Number of Performance Awards Outstanding as of December 31, 2014 Granted Exercised — — Cancelled Outstanding as of June 30, 2015
Summary Of Non-Cash Stock-Based Compensation	Three months ended Six months ended June 30, June 30, 2015 2014 2015 2014 Research and development $ $ $ $ General and administrative $ $ $ $

Commitments (Tables)

Commitments (Tables)	6 Months Ended
	Jun. 30, 2015
Commitments [Abstract]
Future Minimum Lease Payments	2015 2016 2017 Total Minimum lease payments $ $ $ $

Significant Accounting Polici19

Significant Accounting Policies (Narrative) (Details) shares in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015shares	Jun. 30, 2014shares	Jun. 30, 2015USD ($)itemshares	Jun. 30, 2014shares
Significant Accounting Policies [Abstract]
Contractual maturity of a particular investment			1 year
Number of financial institutions | item			1
Impairment charges on marketable securities other-than-temporary declines | $			$ 0
Vesting period of stock options			4 years
Anti-dilutive shares excluded from computation of diluted net loss per share	17.7	5.5	17.7	5

Significant Accounting Polici20

Significant Accounting Policies (Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Numerator:
Net loss	$ (3,374)	$ (3,246)	$ (5,957)	$ (6,695)
Denominator:
Weighted-average shares used in computing net loss per share, basic and diluted	45,356	45,247	45,356	45,187
Net loss per share, basic and diluted	$ (0.07)	$ (0.07)	$ (0.13)	$ (0.15)

Cash, Cash Equivalents And Ma21

Cash, Cash Equivalents And Marketable Securities And Assets Measured At Fair Value (Cash, Cash Equivalents And Marketable Securities) (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014		Jun. 30, 2014	Dec. 31, 2013
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents	$ 36,352	$ 40,590	[1]	$ 44,575	$ 48,588
Cash and cash equivalents, Short Term Investment, Amortized Cost	37,301	40,579
Cash and cash equivalents, Short Term Investment Unrealized Gains	$ 1	$ 1
Cash and cash equivalents, Short Term Investment Unrealized Losses
Accrued Interest		$ 10
Estimated Fair Value, Marketable securities	$ 950
Cash and cash equivalents, Short Term Investment, Fair Value	37,302	40,590
Estimated Fair Value, Fair Value Disclosure [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Short Term Investment, Fair Value	37,302	40,580
Marketable Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, Amortized Cost Basis	949
Available-for-sale securities, Gross Unrealized Gains	$ 1
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest
Estimated Fair Value, Marketable securities	$ 950
Marketable Securities [Member] | Estimated Fair Value, Fair Value Disclosure [Member]
Schedule of Available-for-sale Securities [Line Items]
Estimated Fair Value, Marketable securities	950
Cash [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash	$ 167	$ 295
Available-for-sale securities, Gross Unrealized Gains
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest
Cash and cash equivalents, Fair Value	$ 167	$ 295
Cash [Member] | Estimated Fair Value, Fair Value Disclosure [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Fair Value	167	295
Cash Equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash equivalents	$ 32,286	$ 34,805
Available-for-sale securities, Gross Unrealized Gains
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest
Cash and cash equivalents, Fair Value	$ 32,286	$ 34,805
Cash Equivalents [Member] | Estimated Fair Value, Fair Value Disclosure [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Fair Value	32,286	34,805
Commercial Paper [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, Amortized Cost Basis	4,848	4,848
Available-for-sale securities, Gross Unrealized Gains	$ 1	$ 1
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest
Estimated Fair Value, Marketable securities	$ 4,849	$ 4,849
Commercial Paper [Member] | Estimated Fair Value, Fair Value Disclosure [Member]
Schedule of Available-for-sale Securities [Line Items]
Estimated Fair Value, Marketable securities	4,849	4,849
Corporate Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, Amortized Cost Basis		$ 631
Available-for-sale securities, Gross Unrealized Gains
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest		$ 10
Estimated Fair Value, Marketable securities		641
Corporate Securities [Member] | Estimated Fair Value, Fair Value Disclosure [Member]
Schedule of Available-for-sale Securities [Line Items]
Estimated Fair Value, Marketable securities		631
Cash And Cash Equivalents, Reported Value [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents	$ 36,352	40,579
Available-for-sale securities, Gross Unrealized Gains		$ 1
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest		$ 10
Cash and cash equivalents, Fair Value	$ 36,352	40,590
Cash And Cash Equivalents, Reported Value [Member] | Estimated Fair Value, Fair Value Disclosure [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Fair Value	36,352	40,580
Matures In One Year Or Less [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Short Term Investment, Amortized Cost	37,301	40,579
Available-for-sale securities, Gross Unrealized Gains	$ 1	$ 1
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest		$ 10
Cash and cash equivalents, Short Term Investment, Fair Value	$ 37,302	40,590
Matures In One Year Or Less [Member] | Estimated Fair Value, Fair Value Disclosure [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Short Term Investment, Fair Value	$ 37,302	$ 40,580
Matures One To Three Years [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Short Term Investment, Amortized Cost
Available-for-sale securities, Gross Unrealized Gains
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest
Cash and cash equivalents, Short Term Investment, Fair Value
Matures One To Three Years [Member] | Estimated Fair Value, Fair Value Disclosure [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Short Term Investment, Fair Value
[1]	Derived from the Company's audited financial statements as of December 31, 2014, included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission.

Cash, Cash Equivalents And Ma22

Cash, Cash Equivalents And Marketable Securities And Assets Measured At Fair Value (Assets Measured At Fair Value On Recurring Basis) (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	$ 37,302	$ 40,590
Cash And Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	32,453	35,100
Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	4,849	4,849
Corporate Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value		641
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	32,453	35,100
Level 1 [Member] | Cash And Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	32,453	35,100
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	4,849	5,490
Level 2 [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	$ 4,849	4,849
Level 2 [Member] | Corporate Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value		$ 641
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value
Level 3 [Member] | Cash And Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value
Level 3 [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value
Level 3 [Member] | Corporate Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value

Equity And Stock-Based Compen23

Equity And Stock-Based Compensation Expense (Stock Option And Performance Award Activity) (Details)	6 Months Ended
	Jun. 30, 2015shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance, Number of Options, Outstanding	17,913,182
Number of Options, Granted	595,000
Number of Options, Cancelled	(1,561,161)
Ending Balance, Number of Options, Outstanding	16,947,021
Performance Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance, Number of Options, Outstanding	1,889,465
Number of Options, Granted	50,000
Number of Options, Cancelled	(50,000)
Ending Balance, Number of Options, Outstanding	1,889,465

Equity And Stock-Based Compen24

Equity And Stock-Based Compensation Expense (Summary Of Non-Cash Stock-Based Compensation) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Stock-Based Compensation [Line Items]
Share Based Compensation	$ 881	$ 884	$ 1,844	$ 1,667
Research And Development [Member]
Stock-Based Compensation [Line Items]
Share Based Compensation	289	388	623	736
General And Administrative [Member]
Stock-Based Compensation [Line Items]
Share Based Compensation	$ 592	$ 496	$ 1,221	$ 931

Commitments (Narrative) (Detail

Commitments (Narrative) (Details) - Jun. 30, 2015 - Austin, TX [Member] - ft²	Total
Operating Leased Assets [Line Items]
Office space	6,000
Operating lease expiration year	2017-12

Commitments (Future Minimum Lea

Commitments (Future Minimum Lease Payments) (Details) $ in Thousands	Jun. 30, 2015USD ($)
Contractual Obligation Fiscal Year Maturity Schedule [Abstract]
Future minimum lease payments, 2015	$ 143
Future minimum lease payments, 2016	146
Future minimum lease payments, 2017	147
Total	$ 436